| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | Alector Brain Carrier (ABC) platform assets Neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease) | IND | — | Subscribe to access the data. | Biologics | Nervous System | |
IND Submission example | Alector Brain Carrier (ABC) platform assets Neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease) | IND | — | Subscribe to access the data. | Biologics | Nervous System | |
IND Submission example | Alector Brain Carrier (ABC) platform assets Neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease) | IND | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
GSK plc$52.78
+0.31 (+0.59%)
A 85Pipeline Score Undervalued Pharma · Commercial
Market Cap
102.60 B
EPS
3.88
P/E Ratio
13.44 $
Value Trade
189.20 M
2.45 %
Week
-8.72 %
1 Month
-14.18 %
3 Month
10.52 %
6 Month
31.98 %
5 Year
7,729.33 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
2.87 M
52 Week Range
35.45 - 61.70
% held by Insiders
0.01 %
% held by Institutions
18.76 %
Enterprise Value
122.62 B
Total Shares
2.00 B
Short %
0.42 %
Float Shares
1.99 B
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
A85
Pipeline Score $183.1B
Pipeline ValueUndervalued
Valuation Signal968
Drugs Scored6.0x
rNPV / MCap Top 98%
Large Pharma (rank 19 of 911)
Percentile RankGSK plc earns an A-grade pipeline score (85/100), with $183.4B risk-adjusted pipeline value, led by Otelixizumab in Diabetes Mellitus, Type 1 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albiglutide Monoclonal antibody | Diabetes Mellitus, Type 2 | Phase 3 | NCT01406262 | 61% | $15.8B | COMPLETED | 6,607 | - | - | Dec 29, 2011 | - | Jun 8, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bepirovirsen | chronic hepatitis B | Phase 3 | 2026-05-28 | overall cure rate: 19%; cure rate low viral activity: 26%; low viral activity threshold: 1,000 U/L Read More | GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients Read More | |
bepirovirsen | chronic hepatitis B | Phase 3 | 2026-05-28 | overall cure rate: 19%; cure rate low viral activity: 26%; low viral activity threshold: 1,000 U/L Read More | GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients Read More | |
bepirovirsen | chronic hepatitis B | Phase 3 | 2026-05-28 | overall cure rate: 19%; cure rate low viral activity: 26%; low viral activity threshold: 1,000 U/L Read More | GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GSK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GSK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-14 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-14 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-14 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GSKUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSK's Utebzi (tebipenem pivoxil) has been approved in the United States for the treatment of complicated urinary tract infections (cUTIs) in adults. This approval marks a significant advancement in antibiotic therapies, providing healthcare professionals with a new option to manage these infections. The introduction of Utebzi is expected to enhance patient care in this area.
Read more →GSKGSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients
GSK and Ionis Pharmaceuticals reported that their investigational drug bepirovirsen led to a functional cure in nearly 20% of chronic hepatitis B patients in Phase 3 studies. The results showed a higher success rate in patients with low viral activity. The FDA has granted priority review for bepirovirsen, with regulatory decisions expected soon.
Read more →GSKGSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints
GSK and Alector have halted the Phase 2 study of nivisnebart for Alzheimer's due to lack of efficacy. This failure marks Alector's third setback in recent years, following the discontinuation of another asset, latozinemab. Despite these challenges, analysts remain hopeful about Alector's future prospects and its new ABC platform aimed at neurodegenerative diseases.
Read more →GSKTrump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow
The Trump administration has imposed a 100% tariff on imports of patented pharmaceuticals, effective in 120 days for large companies and 180 days for smaller ones. While some companies have secured exemptions through agreements, others like GSK and Johnson & Johnson are still facing tariffs. Analysts suggest that carve-outs for certain drugs may lessen the overall impact on the industry, but concerns remain regarding the potential harm to smaller biotech firms.
Read more →GSKGSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
GSK presented new data at RSVVW'26 showing that its RSV vaccine, AREXVY, significantly reduces the risk of RSV-related hospitalizations and associated cardiovascular events in adults aged 60 and older. The study demonstrated a 75.6% effectiveness against hospitalization and notable reductions in severe COPD and asthma flare-ups. These findings contribute to the understanding of RSV's impact on health outcomes.
Read more →GSKBig Pharma Tight-Lipped on Details of API Stockpile Deals
GSK, along with Bristol Myers Squibb and Merck, has committed to contribute active pharmaceutical ingredients to the U.S. Strategic Active Pharmaceutical Ingredients Reserve as part of a broader initiative to enhance supply chain resilience. While the agreements are framed as a means to ensure adequate supplies in emergencies, many specifics remain undisclosed, including the origins of the donated materials. This lack of transparency raises questions about the effectiveness and reliability of the initiative.
Read more →GSKGSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
GSK has announced the recipients of its COiMMUNITY Initiative grants, awarding $2 million to 16 organizations aimed at improving vaccination rates in the U.S. The initiative, now in its third year, will also allocate $3 million in 2026 for projects focused on vaccine communication and delivery. Various organizations, including The J.A.M.I.E. Group and Immunize Colorado, will utilize these funds to address barriers to immunization.
Read more →GSKGSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
GSK has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support organizations focused on improving the lives of those affected by lupus. The initiative aims to enhance awareness, diagnosis, and treatment options for lupus patients. Thirteen grantees were selected for their innovative community-led programs. GSK emphasizes its commitment to fostering a connected lupus community.
Read more →GSKSamsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Samsung Biologics has announced the acquisition of Human Genome Sciences from GSK, marking its first U.S.-based manufacturing site in Rockville, Maryland. This strategic acquisition, valued at $280 million, aims to enhance production capacity and support a resilient supply chain for critical biologic medicines. The deal is expected to close by the end of Q1 2026, retaining over 500 employees at the site.
Read more →Competitive Position
How GSK ranks across every disease it competes inCompetitive Position is a premium feature
See how GSK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial